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Abstract: 
Background: Pericardial effusion in pulmonary arterial hypertension (PAH) is an indicator of 
right heart failure and a marker of poor prognosis; its significance on serial transthoracic 
echocardiograms (TTE) is not clear. 
Methods: We examined our database for PAH patients followed at our center (10/99-11/07). 
Baseline and follow-up TTE (1.0±0.5y) and outcomes were studied (N=200). The presence of 
pericardial effusion was evaluated at baseline and follow-up. The persistence or change in 
pericardial effusion status was categorized into four categories. Kaplan Meier methods were used 
to estimate survival functions of the various categories. Cox proportional hazards modeling was 
used to adjust for other covariates and identify independent predictors. 
Results: Over a mean follow-up of 4.6 ± 2.6 y, 53% (n=106) patients died. Pericardial effusion 
was present in 20% (n=40) at baseline and 22% (n=44) during follow up. Patients with 
pericardial effusion at baseline or follow-up had significantly higher creatinine, pulmonary 
vascular resistance, lower cardiac output, and were more likely to be treated with prostanoids. 
During follow-up, there was significantly increased prostanoids (58% vs. 28%) and combination 
therapy (8% vs. 2%) use compared to baseline. New or persistence of pericardial effusion was 
associated with worse outcomes (p<0.001) and an independent predictor of survival after 
adjusting for age, creatinine, sodium, cardiac output, mean right atrial pressure, New York Heart 
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Association (NYHA ) functional class, and presence of connective tissue disease as the etiology 
of PAH (p-value<0.001). 
Conclusion: New or persistent pericardial effusion in PAH despite vasoactive therapy predicts 
worse outcomes; absence or resolution of pericardial effusion with therapy suggests better 
prognosis. Its public health significance is the ability to identify patients that may benefit from 
closer follow-up for reassessment and consideration of more aggressive medical therapy or 
referral for lung transplant to prevent worsening health and/or death. 
v 
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1.0  INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a disease caused by a pathologic increase in 
pulmonary vascular resistance leading to progressive right ventricular (RV) failure and death (1-
6). Pericardial effusion in the presence of PAH is associated with worse right-sided cardiac 
hemodynamics and RV decompensation, and is a predictor of worse outcomes (7-13).  Data 
about the significance of pericardial effusion during follow-up is limited (14). Furthermore, the 
significance of resolution versus persistence of pericardial effusion on serial echocardiograms 
has not been described. We hypothesized that the presence or persistence of pericardial effusion 
during follow-up is associated with RV dysfunction and decreased survival. 
1 
1.1 PULMONARY ARTERIAL HYPERTENSION 
PAH is a condition where the pulmonary arteries become restrictive to blood flow 
through the lungs, leading to elevated right heart pressures  (1). The right side of the heart pumps 
blood into the lungs to collect oxygen and expel carbon dioxide. After the exchange has taken 
place, the blood is returned to the left side of the heart where it is pumped out to the rest of the 
body. Because of the increased resistance to blood flow in the pulmonary arteries in PAH, the 
right side of the heart has to pump harder in order to force the blood to pass through the lungs. 
This causes the right side of the heart to become enlarged overtime and eventually leads to right 
heart failure and death. (1-2) 
  
Figure 1: Pulmonary Arterial Hypertension (a) versus Normal Heart (b).  
 
Notice, in figure one, how the right ventricle (RV) is much larger than the left ventricle 
(LV) in the patient with pulmonary arterial hypertension (PAH).  
PAH (a) 
 LV 
LV 
RV 
RV 
Normal Heart (b) 
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PAH may be a result of an unknown cause (idiopathic PAH), inherited (familial PAH), 
due to birth defects of the heart, liver disease, connective tissue disease, HIV infection, certain 
medications, or other rare conditions (associated PAH). To confirm diagnoses of PAH, patients 
undergo a detailed examination by the physician and are referred for several tests including a 
chest X-ray, computed tomography (CT) scan, transthoracic echocardiogram (TTE), ventilation 
perfusion scan, sleep study, several blood tests, and right heart cardiac catheterization to directly 
measure hemodynamics (the right heart pressures and cardiac output)(15).   
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1.2 PERICARDIAL EFFUSION 
Pericardial effusion refers to fluid that accumulates in the pericardial space (a double 
layered sac that surrounds the heart), and can be detected by using a TTE. Drainage of this fluid 
is referred to as pericardiocentesis. Notice that in figure 2 the presence of pericardial effusion (a) 
versus a normal heart (b). 
 
  
Figure 2: Illustration of (a) Heart with Pericardial Effusion (PE) versus (b) Normal Heart. 
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PE 
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 1.3 SIGNIFICANCE OF RESEARCH 
While presence of pericardial effusion in patients with PAH has been associated with 
poor prognosis, the significance of evolution of pericardial effusion in patients on PAH therapy 
over time is unclear. We believe that patients who do not have a pericardial effusion at both 
baseline and follow-up, represent a lower risk group; versus, patients who have a pericardial 
effusion that persists or develops during follow-up. Such information would be useful to identify 
patients that may benefit from closer follow-up for reassessment and consideration of more 
aggressive medical therapy or referral for lung transplant to prevent getting worse or death.  
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2.0  MATERIALS AND METHODS 
 
2.1 THE STUDY POPULATION 
2.1.1 Sample Selection 
We conducted a retrospective cohort study by reviewing medical records of patients with 
PAH at the University of Pittsburgh Medical Center (UPMC) in Pittsburgh, Pennsylvania. The 
World Health Organization classifies pulmonary hypertension (PH) into five groups based on the 
underlying cause of PH. Our study population was limited to only patients with group 1 
pulmonary arterial hypertension (PAH) as per the Dana Point’s clinical classification version 
(16). Our initial sample of 503 patients was collected from UPMC’s pulmonary hypertension 
registry from October 1999 to November 2008. One hundred twenty six patients had no TTEs 
performed during the study period and were excluded. Six patients were not found to have 
pulmonary hypertension after diagnostic evaluation, and were excluded from the study. An 
additional 83 patients were not considered PAH patient and were also excluded. There were 15 
patients who had a heart or lung transplant before 1999 were excluded from the study. The study 
protocol also required that least two TTEs were performed during the years 1999-2008. 
Consequently, 73 patients with no follow-up TTE in the study period were excluded from the 
study leaving a final sample size of 200 patients. Figure 3 illustrates the derivation of the final 
sample. 
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Patients Collected from UPMC’s PH Registry 
(n=503) 
 
Excluded (n=203) 
No TTE during study period (n=126) 
Not Found to have PH (n=6) 
Not Group 1 PH (n=83) 
Had Heart or Lung Transplant (n=15) 
 
Patients with PAH                       
(n=273) 
Further Exclusions 
Only One TTEs Performed 
within Study Period 
 (n=73) 
Final Sample Included in Study 
Had 2 TTEs Performed within Study 
Period 
 (n=200) 
 
Figure 3: Flow Chart of Final Sample Selection 
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2.1.2  Selection of TTEs  
The first TTE that was performed during years 1999-2007 was selected as each patient’s 
baseline TTE measurement. We then selected a second TTE such that it was performed 
approximately one year from the baseline TTE.  
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2.2 STUDY VARIABLES 
2.2.1 Descriptive Variables 
Table 1 depicts our study variables. Demographics, clinical characteristics, pulmonary 
function tests, and serum biomarker data were collected at baseline. PAH medications, functional 
status and echocardiographic variables were determined at baseline and at the time of the second 
TTE. Hemodynamics was determined approximately 6 months from baseline.  
Table 1: List of Study Variables 
Demographics PAH Medications 
Age Combination Medications 
BMI ET Blocker 
Female No Medication 
Caucasian Prostanoid 
Clinical Characteristics PTE5 Inhibitor 
Coronary Artery Disease Echo Measurements 
Chronic Kidney Disease Pericardial effusion 
Chronic Obstructive Pulmonary Disease Functional Status 
Diabetes Mellitus New York Heart Association 
Hyper Lipidemia Hemodynamics 
Hypertension Fick Cardiac Index 
Obstructive Sleep Apnea Fick Cardiac Output 
Smoking history Pulmonary Artery Mean Pressure 
Etiology PAH Right Arterial Mean Pressure 
Congenital Heart Disease Pulmonary Vascular Resistance  
Cirrhosis Serum Biomarker 
Connective Tissue Disease Albumin 
Familial Pulmonary Arterial Disease Creatinine 
Idiopathic Pulmonary Arterial Disease 
Phen Phen 
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 2.2.2 Pericardial Effusion Status 
The focus of our study was the persistence or change in pericardial effusion status from 
baseline to an approximate one year follow-up date.  In order to categorize this event we created 
a variable called Difference in Pericardial Effusion from Baseline to One Year Follow-up 
(DIFFEFF). Table 2 shows definition of each category of this variable. 
We hypothesized that this categorization would be ordinal with the reasoning that a 
person with no pericardial effusion (category 1) would be medically best off, whereas one whose 
pericardial effusion disappears at follow-up (category 2) is better off than a person who instead 
develops one at follow-up (category 3). Furthermore, we reasoned that a person who has had a 
pericardial effusion at both baseline and follow-up (category 4) is worse off than a person who 
recently developed it at follow-up (category 3). We hypothesized that persistence of pericardial 
effusion over time despite PAH therapy, reflects worse disease severity that is not responding to 
treatment. 
 
 
           
Table 2: Definition of the Variable Difference in Pericardial Effusion from  
Baseline to One Year Follow-up (DIFFEFF) 
Value Presence of Pericardial Effusion 
 TTE 1 TTE 2 
1 Not Present Not Present 
2 Present Not Present 
3 Not Present Present 
4 Present Present 
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2.3 STATISTICAL METHODS 
2.3.1 Survival Analysis 
The main focus of our study was to compare the estimated survival among the difference 
categories of DIFFEFF. We set up our survival problem such that the time of origin for each 
patient was to be the date of their baseline TTE. Furthermore, the event of interest to be observed 
was death. We followed patients starting from their baseline TTE up until death or January 2012; 
whichever came first. Patients surviving beyond January 2012 were considered to be right 
censored. Death was verified using patient medical records and the social security death index.  
 2.3.2 Survival Model 
We used The Kaplan–Meier procedure was used to estimate the survival function of each 
category of DIFFEFF. A test of trend was used to determine whether there was a systematic 
difference among the survival distributions of each category. A p-value <0.05 from the test of 
trend was used to indicate a significant trend among the survival curves. We also tested the 
proportional hazards assumption based on the four survival curves. A p-value <0.05 would 
indicate that the proportional hazards assumption had been violated. A Cox proportional hazard 
model was then built including several covariates to reduce variability and/or to control for 
confounding. Potential covariates were preselected based on principle investigator’s knowledge 
of potential confounding issues. Confounding variables included age, creatinine, fick cardiac 
output, connective tissue disease, mean right arterial pressure, NYHA functional class, and 
sodium.  
11 
2.3.2 Distributional Tests 
Chi-square analysis was used to compare differences between groups, in proportions of 
categorical variables. Two sample t-tests were used to compare means between groups for 
normally distributed continuous variables. Kruskal-Wallis equality of population rank tests were 
used to compare distributions between groups, of non-normally distributed continuous variables. 
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3.0  RESULTS 
 
3.1 DESCRIPTIVES OF SAMPLE 
 
In order to understand our sample, table 3 shows the Demographics and Clinical 
Characteristics of the sample at baseline.  
 
         Table 3: Clinical Characteristics of 200 Patients at Baseline 
Demographics  
Age                   54.1 ± 14.7 
BMI                 29.4 ±  9.0 
Female 90.9% 180    
Caucasian 70.5% 141    
Comorbidities   
Coronary Artery Disease 14% 28    
Chronic Kidney Disease 11.5% 23    
Chronic Obstructive Pulmonary Disease 14% 28    
Diabetes Mellitus 14.5% 29 
Hyper Lipidemia 24.5% 49 
Hypertension 42.2% 84 
Obstructive Sleep Apnea 15% 30 
   History of Smoking 46% 92 
Etiology PAH   
Congenital Heart Disease 11.1% 22 
Cirrhosis 7.1% 14 
Connective Tissue Disease 33.3% 66 
Familial Pulmonary Arterial Disease 1.0% 2 
Idiopathic Pulmonary Arterial Disease 46.5% 92 
Phen Phen 1.0% 2 
Data for continuous variables are presented as mean ± standard deviation and values 
for categorical values are presented as the total number and the percent of subjects 
with that certain attribute. All estimates are based on N=200 excluding BMI where 
N=187. 
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In order to determine what clinical characteristics may be associated with patients with a 
pericardial effusion and those without one, we compared the two groups. Table 4 shows the 
distribution of select certain clinical characteristics between individuals who had a pericardial 
effusion either at baseline and/or follow-up versus those who never had a pericardial effusion at 
either time point. We can see that creatinine is significantly higher in individuals who had a 
pericardial effusion (p-value <0.001). Also the percentage of individual who have connective 
tissue disease is higher in individuals who had a pericardial effusion present at either time point. 
Moreover, individuals who did not have a pericardial effusion at either baseline and/or follow-up 
had lower mean right atrial pressure and pulmonary vascular resistance, and higher fick cardiac 
output. 
Table 4: Results of Comparison of Selected Variables: Individuals who had a Pericardial 
Effusion Present at TTE1 and/or TTE2 versus those who had No Pericardial Effusion Present at 
either. 
Variable All patients 
No pericardial effusion 
at TTE1 or TTE2 
(N=142) 
Pericardial effusion 
present at TTE1 or 
TTE2 (N=58) 
p-value 
Demographics  
Age (y) 54 ± 15 54 ± 15 55 ±  13 0.7 
Female (%) 71 68 76 0.3 
Caucasian (%) 91 92 89 0.4 
BMI (Kg/m2) 29 ± 9 29 ± 9 30 ± 10 0.6 
Creatinine (mg/dl) 1.1 ± 0.6 1.0 ± 0.5 1.3 ± 0.7 0.0003 
NYHA at TTE1 2.5 ± 0.7 2.4 ± 0.7 2.5 ± 0.8 0.8 
NYHA at TTE2 2.4 ± 0.8 2.4 ± 0.7 2.5 ± 0.9 0.2 
IPAH (%) 47 49 43 0.2 
CTD (%) 33 26 50 0.001 
Hemodynamics  
RA mean (mmHg) 10 ± 8 9.2±8.8 11.1±5.6 0.007 
PA mean (mmHg) 48 ± 16 48 ± 17 51 ± 14 0.2 
Fick CO1 (L/min) 5.1 ± 1.9 5.4 ± 1.9 4.6 ± 1.8 0.006 
PVR (Wood units) 8 ± 6 7 ± 6 11 ± 7 0.0003 
Data for continuous variables are presented as mean ± standard deviation and values for categorical values are 
presented as the total number and the percent of subjects with that certain attribute 
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It is important to understand how patients are being treated for PAH because the final 
results we are trying to reach is to determine the prognostic significance of the persistence or 
change in pericardial effusion status from baseline to follow-up despite vasoactive therapy for 
the treatment of PAH.  Table 5 shows the frequency and percentage of individuals on different 
medications or if they are on a combination of medications. The table also shows the New York 
Heart Association (NYHA) functional status of the 200 individuals in our study. We can see that 
the percentage of individuals taking Prostaniods, PTE5 Inhibitors, ET Blockers, Calcium Chanel 
Blockers, and a combination of medications increased from baseline to follow-up. As a result, 
the percentage of individuals taking no medications has significantly decreased. NYHA 
however, appears to have remained the same from baseline to follow-up.  
 
 
Table 5: Pulmonary Arterial Hypertension Medications and Functional Status of 200 Patients  
at Baseline and One Year Follow-up 
PAH Medications Baseline Follow-up 
Medications    
Prostanoid  28.1% 56 41.5% 83 
PTE5 Inhibitor  5.5% 11 19.5% 39 
ET Blocker  37.2% 74 52.3% 104 
Calcium Chanel Blocker  24.5% 49 27.0% 54 
Combination of Medications  2.5% 5 7.5% 15 
No Medications 27% 54 7.5% 15 
Functional Status   
NYHA            2.44± .749 2.41±.786 
Data for continuous variables are presented as mean ± standard deviation and values for medications are 
presented as the total number and percent of subjects with that certain medication; Estimates are based on 
N=200. 
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Table 6 shows the mean time from an approximate date of diagnosis of PAH to the first 
TTE (baseline) in 148 patients. We looked at this time difference in order to get a sense of how 
long patients have had PAH and to determine that one category of DIFFEFF hasn’t on average 
had PAH longer. The overall mean time is 2.4 years with a standard deviation of 2.6 years. The 
Kruskal-Wallis test of equality of populations rank test indicated that the mean times do not 
differ (p-value=0.14) across the DIFFEFF categories.  
 
Table 6: Description of Time (years) between an Approximate Diagnosis of PAH and Baseline 
TTE across DIFFEFF Categories 
DIFFEFF Categories* Mean SD Minimum Median Maximum 
(1) Not Present/ Not Present 2.7 2.7 0 2.1 10.9 
(2) Present/ Not present 1.5 2.5 0 0.1 8.4 
(3) Not Present/Present 1.8 2.0 0 1.1 6.0 
(4) Present/ Present 2.0 2.0 0 1.7 7.4 
Overall 2.4 2.6 0 1.7 10.9 
*Kruskal-Wallis equality of populations rank test across DIFFEFF (p-value=0.14); Time values are presented in 
years; SD=Standard Deviation.; Estimates are based on N=147 (26.5% Missing); DIFFEFF = Difference in 
Pericardial Effusion from Baseline to One Year Follow-up.  
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In our study, the selection of baseline and follow-up TTEs was done such that on average 
we have a one year follow-up period to observe any change in the status of pericardial effusion. 
In Table 7, we described the average time between baseline TTE and follow-up TTE across the 
different categories of DIFFEFF.  The average follow-up appears to be very similar across the 
categories with the highest mean follow-up time being 385.9 days and the lowest mean follow-
up time being 354.6 days. Overall, it appears that the average time between baseline TTE and 
follow-up TTE is 377 days (approximately 1 year). 
 
Table 7: Description of Time between Baseline and Follow-up Echoes across DIFFEFF 
Categories 
DIFFEFF Categories* Mean SD Minimum Median Maximum 
(1) Not Present/ Not Present 381.2 183.2 76 354.5 1491 
(2) Present/ Not present 354.6 141.8 132 358 716 
(3) Not Present/Present 385.9 195 174 357 934 
(4) Present/ Present 363.4 116.0 134 365 658 
Overall 377.4 173.6 76 357 1491 
*Kruskal-Wallis equality of populations rank test across DIFFEFF (p-value= 0.97); Time values are presented in 
days; SD=Standard Deviation.; Estimates are based on N=200; DIFFEFF = Difference in Pericardial Effusion from 
Baseline to One Year Follow-up.  
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3.2 SURVIVAL ANALYSIS 
3.2.1 Survival Data 
According to Table 8, the minimum time an individual was followed until they died or 
were considered censored was 0.3 years. On the other hand, the maximum time an individual 
was followed up until they died or were censored was 11.6 years. Overall, 53% of individuals in 
our study died during the study period. Individuals with a pericardial effusion at both baseline 
and follow-up had the highest percentage (80%) of deaths compared to the other categories. 
Moreover, individuals who had developed a pericardial effusion during follow-up had the second 
highest percentage of deaths (61.1%) when compared to the other categories. Both individuals 
who never had a pericardial effusion or who had one at baseline and then the pericardial effusion 
resolved at follow-up, have similar percentages of death (47.9% & 47.7%).  
Table 8: Description of Survival Data across DIFFEFF Categories 
DIFFEFF Categories 
Number 
of 
Subjects 
Observed 
Deaths 
Time of Follow-up 
Mean SD Minimum Median Maximum 
(1) Not Present/ Not 
Present 142 68 5.0 2.4 0.3 5.4 11.6 
(2) Present/ Not present 15 7 4.8 2.7 1 5.5 8.6 
(3) Not Present/Present 18 11 4.2 3.1 1.1 3.2 11.4 
(4) Present/ Present 25 20 2.5 1.8 0.4 1.6 6.5 
Overall 200 106 4.6 2.6 0.3 4.7 11.6 
Time values are presented in years; SD=Standard Deviation. Estimates are based on N=200; DIFFEFF = 
Difference in Pericardial Effusion from Baseline to One Year Follow-up. 
18 
Tables 9 shows the number of individuals at risk at baseline (time=0), at 5 years, and at 
10 years. Just to note that time of origin for each individual starts as soon as they entered the 
study, some being later in the study period than others. As a result, some individuals were 
censored sooner. 
Table 9: Number of Individuals at Risk across DIFFEFF Categories: 
Time =0, 5, 10 years 
DIFFEFF Categories Time (years) 
0 5 10 
(1) Not Present/ Not Present 142 77 2 
(2) Present/ Not present 15 9 0 
(3) Not Present/Present 18 6 1 
(4) Present/ Present 25 3 0 
 DIFFEFF = Difference in Pericardial Effusion from Baseline to One Year Follow-up. 
19 
3.2.2 Univariable Survival Analysis 
According to the results of the Kaplan Meier survival curve and the univariable 
proportional hazards model (Figure 3 & Table 10), it appears that individuals whose pericardial 
effusion resolves (disappears), do as well as those who never had a pericardial effusion present 
during the initial 1 year period. Furthermore, it appears that individuals who develop a 
pericardial effusion at follow-up may do as well as those individuals never having a pericardial 
effusion present (hazards ratio=1.6 p-value=0.1). Finally, we can see that individuals who have a 
pericardial effusion present at both baseline and follow-up do much worse that those individuals 
who never had a pericardial effusion at either time point (hazards ratio=3.5 p-value=<0.001). 
Over all, the test of trend indicated that there is a significant trend among the categories (p-
value <0.001). This trend may be more prominent in an adjusted model. 
20 
Figure 4: Kaplan Meier survival curves for different categories of Difference in Pericardial Effusion from 
Baseline to One Year Follow-up (DIFFEFF). *P-Value is based on test of trend for the survival functions. 
Table 10: Results of Univariable Cox Proportional Hazards Model: Hazards Ratios, 95% 
Confidence Interval, and p Values for Difference in Pericardial Effusion from Baseline to 
One Year Follow-up (DIFFEFF) 
DIFFEFF Categories Hazard Ratio (95% CI) p Value 
(1) Not Present/ Not Present Reference Category - 
(2) Present/ Not Present 1.0 (0.5-2.2) 0.9 
(3) Not Present/Present 1.6 (0.9-3.1) 0.1 
(4) Present/ Present 3.5 (2.1-5.8) <0.001 
CI = Confidence Interval; DIFFEFF = Difference in Pericardial Effusion from Baseline to One Year Follow-
up. 
(1)
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3.2.3 Multivariable Survival Analysis 
In order to control for potential confounding variables, we built a multivariable model 
including DIFFEFF as well as age, creatinine, Fick cardiac output, connective tissues disease, 
mean RA pressure, NYHA functional class, and sodium. When controlling for the confounding 
variables, we can see that individuals who developed a pericardial effusion at follow-up, do 
significantly worse that those who never had a pericardial effusion at either time point (hazards 
ratio=2.3 p-value=0.03) (Table 11). Also, individuals who had a pericardial effusion present at 
both baseline and follow-up also do much worse than those who never had a pericardial effusion 
at either time point (hazards ratio=3.0 p-value=<0.01). 
Table 11: Results of Multivariable Cox Proportional Hazards Model: Hazards Ratios, 95% 
Confidence Interval, and P-values 
Variables Hazards Ratio 95% CI P-value 
DIFFEFF* 
(2) Present/ Not present 0.9 0.34-2.3 0.8 
(3) Not Present/Present 2.3 1.07-5.15 0.03 
(4) Present/ Present 3.0 1.49-6.15 <0.01 
Age 1.0 0.99-1.02 0.5 
Creatinine 1.4 0.95-1.92 0.1 
Fick Cardiac Output 1.0 0.90-1.15 0.8 
Connective Tissue Disease 1.2 0.73-2.04 0.45 
Mean RA Pressure 1.0 0.99-1.04 0.44 
NYHA Functional Class 1.0 0.79-1.45 0.67 
Sodium 0.9 0.87-0.97 <0.01 
*Baseline Category= (1) Not Present/ Not Present; Overall test of model significance =p-value<0.001.
Proportional Hazards Assumption Test P-value=0.3134. 
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3.3 PERICARDIOCENTESIS 
 
In our study population, 2 patients underwent pericardiocentesis (drainage of fluid from 
pericardial space). One patient had severe PAH secondary to systemic sclerosis and presented 
electively for pericardiocentesis of a large effusion. After 670 ml of fluid was removed, she 
developed respiratory distress and hypotension requiring brief intubation and inotropic support 
(dobutamine). She was discharged after a weeklong hospitalization and repeat TTE 2 weeks later 
showed no pericardial effusion. She was alive at the last point of contact within our hospital 
system 5 years later. 
The second patient also had scleroderma and PAH admitted to the hospital with rapid 
atrial fibrillation and noted to have a large pericardial effusion with evidence of increased 
pericardial pressures. Consequently 1100 ml of fluid was removed and another 830 ml were 
drained 2 days later without complications. He was discharged 7 days later with a trivial 
pericardial effusion. A repeat echocardiogram 1 year later showed no effusion. He died about 3.4 
years after initial pericardiocentesis. 
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3.4 SENSITIVITY ANALYSIS 
Our study design was to include patients who had two consecutive TTEs one year apart. 
We wanted to make conclusions that were based on a one year follow-up period. As we found 
much variability in the length of time between baseline and follow-up TTEs (e.g., 76 to 1491 
days) a more homogeneous subgroup needed to be identified. A subsample of individuals with 
follow-up times between 10 to 14 months was identified and contained 42% of the patients. We 
performed a reanalysis using this subsample.  
We found that, similar to our original results, individuals who develop a pericardial 
effusion at follow-up as well as those whose pericardial effusion persists to follow-up, both do 
significantly worse than individuals who never had a pericardial effusion at either baseline or 
follow-up. Furthermore, the test of trend was also significant (p-value <0.0001), indicating a 
systematic difference among the survival distributions of DIFFEFF.  
The only difference that was found was in the multivariable model. When adjusting for 
age, creatinine, sodium, cardiac output, mean right atrial pressure, New York Heart Association 
(NYHA) functional class, and the presence of connective tissue disease as the etiology of PAH, 
it was found that category 3 and 4 of DIFFEFF had different hazards ratios when compared to 
our original results. To address this issue, we went back to our original sample and tested 
whether or not categories 3 and 4 were significantly different from each other. It was found that 
they did not differ (p-value=0.09). We then tested it again in our sub-sample, and also they were 
not found to differ.  
We can conclude that by limiting our sample to individuals who had follow-up periods 
greater than or equal to 10 months and less than or equal to 14 months, we also get results similar 
to that of our original sample. 
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4.0  DISCUSSION 
This study shows that pericardial effusion is common during management of patients 
diagnosed with PAH and is prognostically significant. It is the first study to show that pericardial 
effusion in PAH patients is dynamic and this change in pericardial effusion over time is 
important in regards to survival. 
Pericardial effusion in PAH has been consistently found to be a predictor of decreased 
survival (7-14). Recently, the appearance of new pericardial effusion in PAH patients have been 
also found to be prognostically significant in a single center retrospective study (14), and our 
study is consistent with these findings.  In our study, we assessed patients by TTE at two time 
points from the time of initial diagnosis of PAH and found that the presence of pericardial 
effusion was a predictor of mortality at both time points. Furthermore, the change in pericardial 
effusion derived by considering both the time points of TTE 1 and 2 revealed the most useful 
prognostic information which remained independently predictive in a model that also includes 
age, creatinine, sodium, cardiac output, mean right atrial pressure, NYHA functional class, and 
presence of connective tissue disease as the etiology of PAH. Currently, guidelines for 
longitudinal assessment of patients with established PAH are lacking (1). Our study suggests that 
pericardial effusion may be a potential marker for assessing PAH patients over time, but this will 
need confirmation in larger prospective studies.   
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Pericardiocentesis for a large effusion was performed in 2 patients in our study, one of 
whom had to be admitted to the coronary care unit for hypotension and respiratory failure after 
the procedure, however there were no immediate deaths attributed to the procedure. 
Pericardiocentesis in the setting of PAH is an uncommon procedure largely due to the 
notoriously high complication rate (16). As such, management of large effusions has generally 
been by medical optimization of PAH therapy rather than therapeutic drainage. 
Limitations of our study include a retrospective design leading to right heart 
hemodynamics being unavailable in 15% of patients during the study period. Right heart 
hemodynamics was also not obtained at the same time of the TTE. The six-minute walk test was 
not routinely performed during the study period and was therefore not available for analysis. 
Moreover, information about the date of diagnosis of PAH is unknown in 26% of individuals in 
our study.  
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5.0  CONCLUSION 
Pericardial effusion is dynamic in patients with PAH and serial follow-up for resolution 
versus persistence is prognostically valuable and may be a useful marker for the longitudinal 
follow-up these patients. 
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